Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ABBV · NYSE · United States · Pharmaceutical Preparations
In shortAbbVie Inc. is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 24.6% | 99/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 6.9% | 48/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 15367.3% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 15.7% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.67× | 0/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 3.77× | 7/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.21× | 35/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.34 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 29.1% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 4.22× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 10.6% | 72/100 |
| Operating margin volatility | 6.4% | 51/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 1.8% | 26/100 |
|---|---|---|
| EPS growth, 3-year average | -29.1% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 56,197 | 58,054 | 54,318 | 56,334 | 61,160 |
| Cost of revenue | 17,446 | 17,414 | 20,415 | 16,904 | 18,204 |
| Gross profit | 38,751 | 40,640 | 33,903 | 39,430 | 42,956 |
| Research & development | 6,922 | 6,510 | 7,675 | 12,791 | 9,096 |
| Selling, general & admin | 12,349 | 15,260 | 12,872 | 14,752 | 14,010 |
| Operating income | 17,924 | 18,117 | 12,757 | 9,137 | 15,075 |
| Interest expense | 2,423 | 2,230 | 2,224 | 2,808 | 2,893 |
| Pre-tax income | 12,989 | 13,477 | 6,250 | 3,716 | 6,597 |
| Income tax | 1,440 | 1,632 | 1,377 | (570) | 2,364 |
| Net income | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Diluted shares (millions) | 1,777 | 1,778 | 1,773 | 1,773 | 1,773 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.34 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 3, 2026